Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1c

Autor:	Irene Romera, Jesús Reviriego, R. Gentilella, Esteban Jódar, Luis Alberto Vázquez, Ignacio Conget, Jeremie Lebrec
Jazyk:	angličtina
Rok vydání:	2020
Předmět:	Blood Glucose medicine.medical_specialty Endocrinology Diabetes and Metabolism Recombinant Fusion Proteins Glucagon-Like Peptides Insulin Glargine 030209 endocrinology & metabolism 030204 cardiovascular system & hematology Hypoglycemia Gastroenterology Drug Administration Schedule 03 medical and health sciences 0302 clinical medicine Endocrinology Diabetes mellitus Internal medicine Insulina Post-hoc analysis Internal Medicine medicine Endocrinología Humans Hypoglycemic Agents Glycated Hemoglobin Metabolismo Insulin glargine business.industry Type 2 Diabetes Mellitus medicine.disease Confidence interval Immunoglobulin Fc Fragments Diabetes Mellitus Type 2 Serum glucose Dulaglutide Drug Therapy Combination business medicine.drug
Popis:	Aims. To determine the early benefit:risk balance of dulaglutide versus insulin glargine in patients with type 2 diabetes mellitus (T2DM). Methods. This post hoc analysis used data from a randomized, open-label study (AWARD-2; modified intention-to-treat group) in which suboptimally controlled metformin + glimepiride-treated patients received dulaglutide 1.5 mg (n = 273) or insulin glargine (n = 262). Two composite endpoints were used: for weeks 2–20, fasting serum glucose (FSG)
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca68c32b19006002d2bab2226b16d6e3 https://hdl.handle.net/11268/11220 Zobrazit plný text záznamu